ARA-290 vs Thymulin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
- Half-Life
- ~2–4 hours (SC administration)
- ~30 minutes active half-life
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 20-30 mcg
- Frequency
- Once daily
- 10 days per month (Khavinson protocol)
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Enhances T-cell maturation and differentiation
- Boosts NK cell cytotoxic activity
- Reduces inflammatory cytokine production (TNF-α, IL-1)
- Anti-nociceptive (pain-reducing) properties
- Restores age-related immune decline
- Anti-inflammatory via serotonin pathway modulation
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Injection site reactions
- Mild fatigue initially as immune system activates
- Stacks With
- —
- —